KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $1.3 billion.

  • Vertex Pharmaceuticals' Short-term Investments rose 483.16% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 483.16%. This contributed to the annual value of $1.5 billion for FY2024, which is 8208.9% up from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Short-term Investments stood at $1.3 billion for Q3 2025, which was up 483.16% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Short-term Investments ranged from a high of $1.5 billion in Q4 2024 and a low of $274.5 million during Q4 2022
  • For the 5-year period, Vertex Pharmaceuticals' Short-term Investments averaged around $945.4 million, with its median value being $849.2 million (2023).
  • In the last 5 years, Vertex Pharmaceuticals' Short-term Investments plummeted by 6239.21% in 2022 and then surged by 20936.25% in 2023.
  • Over the past 5 years, Vertex Pharmaceuticals' Short-term Investments (Quarter) stood at $729.9 million in 2021, then tumbled by 62.39% to $274.5 million in 2022, then surged by 209.36% to $849.2 million in 2023, then skyrocketed by 82.09% to $1.5 billion in 2024, then decreased by 12.86% to $1.3 billion in 2025.
  • Its Short-term Investments was $1.3 billion in Q3 2025, compared to $1.4 billion in Q2 2025 and $1.5 billion in Q1 2025.